

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned 10/807,429
				Filing Date	24 March 2004
				First Named Inventor	Wing CHEUNG et al.
				Art Unit	Unassigned 1631
				Examiner Name	Unassigned 10/807,429
Sheet	1	of	2	Attorney Docket Number	38081-00037

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MA	A1	4,732,889	03/1988	CYN Shi et al.	
	A2	4,748,600	05/1988	URQUHART	
	A3	5,354,934	10/1994	PITT et al.	
	A4	5,4169,071	05/1995	IGARI et al.	
	A5	5,541,158	07/1996	VANCE et al.	
	A6	5,674,534	10/1997	ZALE et al.	
	A7	5,739,277	04/1998	PRESTA et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
MA	A8	JP 2-96535	04/1990			✓

Applicant's unique citation designation number (optional). * See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
MA	A9	SALMONSON, T., "Pharmacokinetic and Pharmacodynamic Studies on Recombinant Human Erythropoietin," <i>J. Uro. Nephrol. Suppl.</i> 1990 0(129), pp 1-66 (Abstract) BIOSIS No. 1990:497818			
MA	A10	MATSUSHIA, et al., "A computer program (PPMODELS) with NeXTSTEP for calculating distribution of drugs based on physiological pharmacokinetic model," <i>Sch. Med., Kanazawa Univ</i> 1996 22(2) pp 123-132 (Abstract)			
MA	A11	PHYSICIANS DESK REFERENCE, 51 st ed. (1997) pp 489-495 Medical Economics Company, Inc., Montvale, NJ.			
MA	A12	WICHMANN, et al., "A mathematical model of erythropoiesis in mice and rats," <i>Cell Tissue Kinet</i> , (1989) 22(1) pp 31-49.			
MA	A13	COLBURN et al., "Pharmacokinetic Analysis of Drug Concentration Data Obtained during Repetitive Drug Administration," <i>J. Pharmaceutical Sci.</i> (1977) 66(4) 66 530-533			
MA	A14	WALTON, et al., "Computer support for determining drug dose systematic review and meta-analysis," <i>Brit. Medical Journal</i> (1999) 318 pp 984-990			
MA	A15	McMAHON, et al., "Pharmacokinetic and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers," <i>Blood</i> (1990) 76(9) pp 1718-1722			

Examiner Signature	<i>MA Moran</i>	Date Considered	6/10/05
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Unassigned 10/807,429
				Filing Date	24 March 2004
				First Named Inventor	Wing CHEUNG et al.
				Art Unit	Unassigned- 1631
				Examiner Name	Unassigned 10/807,429
				Attorney Docket Number	38081-00037
Sheet	2	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)				

Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
MSM	A16	HU, et al., "Comparison of Some Control Strategies for Three-Compartment PK/PD Models," <i>J. of Pharmacokinetics and Biopharmaceutics</i> , Biopharmaceutics 1994 22(6) pp 525-550		
MSM	A17	GOBBURU, "Role of dosage regimen in controlling indirect pharmacodynamic responses," <i>Adv. Drug Delivery Reviews</i> , (1998) 33 pp 221-233		
MSM	A18	PORT, R.E. et al., "Predicting the time course of hemoglobin in children treated with erythropoietin for renal anemia," <i>Br. J. Clin. Pharmacol</i> (1998) 46(5) pp 461-466		

Examiner Signature	MA Moran	Date Considered	6/10/05
-----------------------	----------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.